Equities research analysts forecast that Integra Lifesciences Holdings Corp (NASDAQ:IART) will post $0.59 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Integra Lifesciences’ earnings. The highest EPS estimate is $0.60 and the lowest is $0.58. Integra Lifesciences reported earnings of $0.45 per share in the same quarter last year, which would indicate a positive year over year growth rate of 31.1%. The business is expected to report its next quarterly earnings results on Thursday, October 25th.

According to Zacks, analysts expect that Integra Lifesciences will report full-year earnings of $2.40 per share for the current year, with EPS estimates ranging from $2.39 to $2.44. For the next year, analysts expect that the company will post earnings of $2.73 per share, with EPS estimates ranging from $2.66 to $2.76. Zacks’ EPS averages are an average based on a survey of research firms that cover Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Wednesday, July 25th. The life sciences company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The business had revenue of $366.20 million during the quarter, compared to the consensus estimate of $368.08 million. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. The business’s quarterly revenue was up 29.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.45 earnings per share.

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald restated a “hold” rating and issued a $59.00 target price on shares of Integra Lifesciences in a research note on Tuesday, June 12th. Zacks Investment Research downgraded shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Citigroup downgraded shares of Integra Lifesciences from a “buy” rating to a “neutral” rating and upped their target price for the company from $64.00 to $66.00 in a research note on Monday, July 2nd. BTIG Research restated a “buy” rating and issued a $69.00 target price on shares of Integra Lifesciences in a research note on Wednesday, September 12th. Finally, Oppenheimer set a $74.00 target price on shares of Integra Lifesciences and gave the company a “buy” rating in a research note on Friday, June 1st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $61.38.

In other Integra Lifesciences news, Director Stuart Essig sold 159,752 shares of the stock in a transaction on Tuesday, July 10th. The shares were sold at an average price of $64.01, for a total transaction of $10,225,725.52. Following the transaction, the director now directly owns 1,539,019 shares in the company, valued at approximately $98,512,606.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Glenn Coleman sold 8,916 shares of the stock in a transaction on Thursday, August 9th. The shares were sold at an average price of $63.00, for a total transaction of $561,708.00. Following the transaction, the vice president now owns 16,795 shares in the company, valued at $1,058,085. The disclosure for this sale can be found here. Insiders have sold a total of 270,892 shares of company stock worth $17,280,372 over the last quarter. 5.10% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. boosted its stake in Integra Lifesciences by 0.5% during the 1st quarter. Russell Investments Group Ltd. now owns 196,998 shares of the life sciences company’s stock valued at $10,902,000 after acquiring an additional 1,041 shares during the last quarter. Mason Street Advisors LLC lifted its position in shares of Integra Lifesciences by 6.7% in the 1st quarter. Mason Street Advisors LLC now owns 17,634 shares of the life sciences company’s stock worth $976,000 after buying an additional 1,101 shares during the last quarter. Great West Life Assurance Co. Can lifted its position in shares of Integra Lifesciences by 1.4% in the 1st quarter. Great West Life Assurance Co. Can now owns 83,901 shares of the life sciences company’s stock worth $4,644,000 after buying an additional 1,153 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of Integra Lifesciences by 6.1% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 25,390 shares of the life sciences company’s stock worth $1,405,000 after buying an additional 1,450 shares during the last quarter. Finally, LPL Financial LLC lifted its position in shares of Integra Lifesciences by 28.6% in the 1st quarter. LPL Financial LLC now owns 6,840 shares of the life sciences company’s stock worth $376,000 after buying an additional 1,523 shares during the last quarter. Hedge funds and other institutional investors own 84.41% of the company’s stock.

Shares of IART stock traded up $0.47 on Monday, hitting $63.68. The stock had a trading volume of 610,100 shares, compared to its average volume of 740,781. The company has a market capitalization of $5.38 billion, a PE ratio of 32.82, a price-to-earnings-growth ratio of 1.95 and a beta of 0.57. The company has a current ratio of 3.52, a quick ratio of 2.27 and a debt-to-equity ratio of 1.10. Integra Lifesciences has a 52-week low of $41.51 and a 52-week high of $67.50.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.